#Dana-Farber Cancer Institute

In a recent study, Dana-Farber scientists and others uncovered a key part of why some patients eventually become resistant to Venclexta.

The disparity is likely due in part to a low representation of minority physicians in cancer subspecialties.

A study shows how “epigenetic” changes can lead to the development of certain cancers, and how to short-circuit the cancer-causing machine...

“To understand cancer better, we need the combination of chemistry, biology, chemical biology, computational biology and bioinformatics.”

In a study, the test proved able to detect and localize more than 20 types of cancer with a high degree of accuracy.

The findings could help identify patients who might benefit from combination therapy with a checkpoint blocker and another inhibitor.

Researchers are learning how best to use this powerful modality while avoiding serious toxicities.

The findings hold particular promise for people who haven’t been helped by the targeted drug tagraxofusp.

This type of ovarian cancer is the deadliest form of the disease largely because it doesn’t respond to chemotherapy.

Jeffrey Meyerhardt, MD, MPH, answers common questions about treatment and research, family history, and ways that you can reduce your risk.

Dana-Farber researchers have shown that the mutated copy of the gene TP53 sabotages the normal, healthy copy.

The concern around burnt food increasing the risk of cancer relates to the chemicals that form when food is overcooked or burnt.

Scientists are combining immunotherapy agents to try to jump-start the immune system against solid tumors in children.

When Dana-Farber’s Catherine Wu, MD, was a newly minted physician in the mid-90s, there was just one major form of immunotherapy for cancer.

The combination of chemoimmunotherapy with a targeted drug represents a step toward a new standard of care for people with CLL.

For now, there is insufficient evidence to conclude that consuming GMOs can increase your cancer risk.